Muscle Cell Biology, Pathophysiology, and Therapeutics
Funded Grant
Overview
Affiliation
View All
Overview
description
Abstract This application seeks the competitive renewal of the Muscle Cell Biology Pathogenesis and Therapeutics, an interdisciplinary T32 training program in muscle cell biology, pathophysiology, and therapeutics at UCLA. Also referred to as MyoPath, it is the only UCLA program exclusively focused on muscle research that also integrates fundamental laboratory training with translational and clinical exposure. Led by a cohesive and collaborative faculty, MyoPath provides rigorous research training in the cellular, molecular, and genetic mechanisms of muscle development, function, and disease. The program integrates deeply with UCLA’s clinical enterprises, including the Neuromuscular Program, the ATLAS Community Health Project, and the Center for Duchenne Muscular Dystrophy (CDMD). These collaborations expose trainees to clinical research, patient communities, and opportunities to work with clinical samples and technologies. Collectively, these resources support the following Specific Aims: Specific Aim 1: Equip postdoctoral fellows with broad basic-to-translational research skills through immersive training, professional development, and integrated career networking. Specific Aim 2: Accelerate the careers of nationally recruited predoctoral fellows through rigorous training led by top-tier mentors in muscle biology and disease. In the last, still ongoing cycle, we filled 6 of the 6 predoctoral and 2 of the 2 postdoctoral T32 slots annually on a competitive basis. Our T32 has never experienced a shortfall in competitive applications such that positions went unfilled. Therefore, we request to continue with six predoctoral training slots per year and two postdoctoral positions per year, one of which will be prioritized for a clinical fellow to conduct research. Each training position will provide a maximum of three years of support. The program’s strength lies in its cross-disciplinary mentorship, translational research focus, and embedded partnerships with the NIH Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center and the top-ranked NIH- funded UCLA Clinical and Translational Science Institute (CTSI). These collaborations ensure that trainees are exposed to the full spectrum of research, from basic discovery to therapeutic development and clinical application in a highly supportive environment that provides the necessary resources for success. UCLA’s Neuromuscular Program is a major hub for clinical trials in neuromuscular disorders, and trainees benefit from direct access to clinical investigators, human samples, and patient-centered research. Additionally, strong relationships with industry partners expose trainees to career paths in biotechnology and drug development. MyoPath fosters a vibrant training environment with individualized career guidance, structured professional development, and opportunities to present research and build networks within academia, industry, and the clinic. MyoPath trainees are well-prepared to pursue impactful careers as independent investigators and translational scientists equipped to address the challenges of neuromuscular disease. Renewal of this program will continue to build a diverse and exceptional workforce dedicated to advancing muscle biology and therapy development.
